Volumetric quantification revealed a significant decrease in CD9 immunoreactivity in the mPFC region of hNSC‐EV‐treated AD mice at 10 weeks post‐EV treatment compared to the vehicle‐treated AD group (Figure 4A; p < 0.01). The gene discussed is CD9; the disease is Alzheimer disease.